Daratumumab Archives - Medical Conferences

PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM

Presented By

Prof. Pieter Sonneveld, Erasmus University Medical Center, the Netherlands

Trial

Phase 3, PERSEUS

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

Daratumumab shows promise in systemic lupus erythematosus

Presented By

Dr Tobias Alexander, Charité-University Medicine Berlin, Germany

Trial

Phase 2

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:35

KdD outperforms Kd in R/R MM also in participants with poor renal function

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, CANDOR

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:58

Novel standard-of-care in newly diagnosed MM

Presented By

Prof. Pieter Sonneveld, Erasmus MC, the Netherlands

Trial

Phase 3, Perseus

Conference

ASH 2023

Type

Peer-reviewed article

6 February 2024 16:34

CAR T cells rise to the front in multiple myeloma

Expert

Dr Sergio Giralt, Memorial Sloan Kettering Cancer Center, USA

Trial

Phase 3, KarMMa-3

17 April 2023 12:45

Deep and durable responses for quadruple therapy in smouldering MM

Presented By

Prof. Shaji Kumar, Mayo Clinic, MN, USA

Trial

Phase 2, ASCENT

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:04

GRIFFIN: Sustained responses of daratumumab plus RVd in MM

Presented By

Dr Jacob Laubach, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 2, GRIFFIN

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:30

Mechanisms of D-KRd treatment failure in MM identified

Presented By

Dr Eileen Boyle, NYU Langone Health, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:22

TRIMM-2: Favourable results of talquetamab plus daratumumab for MM

Presented By

Dr Ajai Chari, Mount Sinai School of Medicine, NY, USA

Trial

Phase 1, TRIMM-2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:16

ASH 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASH 2021

4 January 2022 08:00

MAIA results confirm superior efficacy of daratumumab with standard-of-care

Presented By

Prof. Thierry Facon, University of Lille, France

Trial

Phase 3, MAIA

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:46

ANDROMEDA: Addition of daratumumab showed superior efficacy in patients with AL amyloidosis

Presented By

Prof. Efstathios Kastritis, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, ANDROMEDA

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:31

Subcutaneous daratumumab plus pomalidomide and dexamethasone in R/R MM

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, APOLLO

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:26

Daratumumab for light-chain amyloidosis

Presented By

Dr Efstathios Kastritis, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, ANDROMEDA

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 10:49

Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM

Presented By

Prof. Saad Usmani, UNC-Chapel Hill School of Medicine, USA

Trial

Phase 3, CANDOR

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 19:49

ALCYONE: New overall survival results for myeloma

Presented By

Dr Maria Victoria Mateos, University Hospital of Salamanca, Spain

Trial

Phase 3, ALCYONE

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 16:16

CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma

Presented By

Prof. Phillippe Moreau, University Hospital of Nantes, France

Trial

Phase 3, CASSIOPEIA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 23:30

Higher levels of treatment satisfaction without compromising efficacy: subcutaneous daratumumab in RRMM

Presented By

Prof. María-Victoria Mateos , University of Salamanca, Spain

Trial

Phase 3, COLUMBA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 21:36

Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone in patients with newly diagnosed amyloid light chain amyloidosis

Presented By

Prof. Raymond Comenzo, Tufts University, USA

Trial

Phase 3, ANDROMEDA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 19:40

Daratumumab a promising treatment option for transplant-eligible multiple myeloma

Presented By

Dr Philippe Moreau, University Hospital Hôtel-Dieu, France

Trial

Phase 3, CASSIOPEIA

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 23:14